Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Stock Short Interest Report for October

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Get Free Report) saw a large increase in short interest in October. As of October 30th, there was short interest totaling 12,075 shares, an increase of 70.8% from the October 15th total of 7,070 shares. Based on an average daily volume of 8,654 shares, the short-interest ratio is presently 1.4 days. Currently, 0.2% of the company’s stock are short sold.

Cryo-Cell International Price Performance

CCEL stock traded down $0.30 during trading hours on Monday, reaching $4.55. The stock had a trading volume of 22,061 shares, compared to its average volume of 15,681. The stock has a market capitalization of $36.67 million, a PE ratio of -19.78 and a beta of 0.45. The stock has a 50-day simple moving average of $4.47 and a 200 day simple moving average of $3.76. Cryo-Cell International has a fifty-two week low of $2.72 and a fifty-two week high of $5.45.

Cryo-Cell International (NYSEAMERICAN:CCEL – Get Free Report) last released its quarterly earnings data on Friday, October 9th. The company reported $0.16 earnings per share for the quarter. The firm had revenue of $7.82 million for the quarter.

Hedge Funds Weigh In On Cryo-Cell International

An institutional investor recently raised its position in Cryo-Cell International stock. Susquehanna International Group LLP grew its position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Free Report) by 40.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,064 shares of the company’s stock after buying an additional 4,046 shares during the period. Susquehanna International Group LLP owned approximately 0.17% of Cryo-Cell International worth $45,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

(Get Free Report)

Cryo-Cell International provides stem cell processing and cryogenic storage services, primarily for families preserving cells collected at childbirth. Its core services include processing and storing umbilical cord blood and cord tissue for potential future medical use. Founded in 1989, the company is based in Oldsmar, Florida, and is among the early private cord blood banking businesses in the United States. It serves customers in the U.S. and reaches international markets through distribution relationships.

See Also

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.